Trial Profile
A Double-blind, Randomized, Placebo Controlled Clinical Trial on Comparing Escitalopram and Duloxetine add-on for Negative Symptoms in Schizophrenic Subjects With Neuregulin-1 (NRG1) Risk Genotype.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Duloxetine (Primary) ; Escitalopram (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms TANESN
- 06 Mar 2010 New trial record